Search Results
Dr. Jason Luke Describes Results from the Phase III COMBI-d Trial
Dr. Jason Luke Talks About Advances in how Melanoma is Diagnosed
Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma
COMBI-d: a phase III study on the combination of dabrafenib and trametinib in patients with melanoma
Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma
Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic
Dr. Jason Luke Discusses Nivolumab and Pembrolizumab in Melanoma
Dr. Jason Luke Discusses the Giants of Cancer Care Program
Professor Jason J. Luke: - The cancer treatment landscape is exploding with possibilities
Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma
COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma
Dr. Luke on Treatment Options in Metastatic Melanoma